Patents by Inventor Stephen R. COMEAU

Stephen R. COMEAU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230117565
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Application
    Filed: June 13, 2022
    Publication date: April 20, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Publication number: 20230002509
    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
    Type: Application
    Filed: March 2, 2022
    Publication date: January 5, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Andrew Nixon, Jon A. Kenniston, Stephen R. Comeau
  • Publication number: 20220411533
    Abstract: The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 29, 2022
    Inventors: Paul ADAM, Stephen R. COMEAU, Philip Nicholas GORMAN, Pankaj Gupta, Priyanka GUPTA, Karl-Heinz HEIDER, Srinath KASTURIRANGAN, Renate KONOPITZKY, Klaus-Peter KUENKELE, Sandeep KUMAR, Taneisha Ann-Tanara MACK, Elinborg Katrin OSTERMANN, Abdulsalam SHAABAN, David WEISMANN, Andreas WERNITZNIG, David S. YOUNG
  • Patent number: 11390687
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: July 19, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Patent number: 11299553
    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: April 12, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Andrew Nixon, Jon A. Kenniston, Stephen R. Comeau
  • Publication number: 20210230299
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Application
    Filed: December 29, 2020
    Publication date: July 29, 2021
    Applicant: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Patent number: 10913802
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Publication number: 20190185580
    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
    Type: Application
    Filed: November 26, 2018
    Publication date: June 20, 2019
    Applicant: Dyax Corp.
    Inventors: Andrew Nixon, Jon A. Kenniston, Stephen R. Comeau
  • Publication number: 20190002584
    Abstract: Disclosed herein are anti-Factor Xlla antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 3, 2019
    Applicant: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Publication number: 20180118851
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis. One aspect of the present disclosure is a bispecific antibody, comprising: a first polypeptide that comprises a light chain of a first antibody, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL) (e.g., a kappa light chain or a lambda light chain); and a second polypeptide that comprises a heavy chain of the first antibody, the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH).
    Type: Application
    Filed: December 31, 2015
    Publication date: May 3, 2018
    Applicant: Dyax Corp.
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Publication number: 20160017055
    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Applicant: Dyax Corp.
    Inventors: Andrew NIXON, Jon A. KENNISTON, Stephen R. COMEAU